Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $42.71M rose 240.0% year over year, ahead of the +115.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 55.4% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 13 analysts of $3.4M (-94.3%) for the fiscal year ending Dec 2026, a slowdown from the +4.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $42.71M+55.4% QoQ
- Last fiscal yearDec 2025
- $59.08M+4.9% YoY
- LTMSep 2026
- $117.61M+115.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 59.08M USD
- Year-over-year change
- +4.9%
- 4-year CAGR
- +5.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.08M | +4.9% |
| FY2024 | 2024-12-31 | 56.31M | +33.9% |
| FY2023 | 2023-12-31 | 42.05M | -29.4% |
| FY2022 | 2022-12-31 | 59.55M | +26.5% |
| FY2021 | 2021-12-31 | 47.08M | — |
Selling, General & Admin vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 selling, general & admin of $117.61M is the 6th highest of the 10 companies compared; the peer median is $139.03M.
- Its year-over-year change of +115.1% is the highest of 10, against a peer median of +24.7%.
- Over three fiscal years its annual growth of -0.3% compares with a peer median of +15.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.43B | +24.9% | +15.4% | 38.5% | |
| LTM Jun 2026 | $712.67M | +55.0% | +53.0% | 91.8% | |
| LTM Sep 2026 | $646.09M | +23.5% | +14.1% | 53.7% | |
| LTM Jun 2026 | $560.88M | +68.6% | +8.8% | 67.5% | |
| LTM Jun 2026 | $139.03M | +19.2% | +2.4% | 3857.6% | |
| LTM Sep 2026 | $117.61M | +115.1% | -0.3% | — | |
| LTM Sep 2026 | $94.24M | +24.7% | +34.4% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M | +37.9% | +181.0% | 171.4% |
| LTM Dec 2025 | $12.8M | +10.2% | +1.9% | — | |
| Peer median (excluding PRAX) | $139.03M | +24.7% | +15.4% | 79.7% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.45M | 8.55M | 0 |
| Cost of Revenue | 0 | 154.44M | 86.77M | 152.41M | 140K |
| Gross Profit | 0 | (154.44M) | (84.32M) | (143.86M) | (140K) |
| Gross Margin | — | — | -3445.8% | -1682.0% | — |
| Research & Development | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| Selling, General & Admin | 47.08M | 59.55M | 42.05M | 56.31M | 59.08M |
| Operating Expenses | 167.33M | 60.55M | 42.05M | 56.31M | 326.06M |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| EBITDA | (166.88M) | (213.57M) | (122.85M) | (182.46M) | (303.13M) |
| EBITDA Margin | — | — | -5020.2% | -2133.3% | — |
| Operating Income | (167.33M) | (214.99M) | (126.37M) | (200.17M) | (326.2M) |
| Operating Margin | — | — | -5164.4% | -2340.3% | — |
| Interest Income | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 271K | 957K | 3.1M | 17.35M | 22.93M |
| Income Before Tax | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Pre-Tax Margin | — | — | -5037.9% | -2137.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Net Margin | — | — | -5037.9% | -2137.5% | — |
| EPS (Basic) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| EPS (Diluted) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| Weighted Avg Shares | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
| Weighted Avg Shares (Diluted) | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.